¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cross reactive antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen competition
    Ç׿ø°æÀï
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • antigen presentation
    Ç׿øÁ¦½Ã
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen recognition
    Ç׿øÀνÄ
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • maltese cross
    ¸»Å×½º½ÊÀÚÇü
  • testosterone cross-reactivity
    ³²¼ºÈ£¸£¸ó±³Â÷¹ÝÀÀ¼º
  • direct cross matching
    Á÷Á¢±³Â÷½ÃÇè
  • innervated cross finger flap
    ½Å°æÁö¹è¼Õ°¡¶ô±³Â÷ÇÇÆÇ
  • plasma cross matching
    (¢¡cross matching) Ç÷Àå±³Â÷½ÃÇè
  • nerve cross over
    ½Å°æ±³Â÷¼ú
  • antigen
    Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø
  • antigen competition
    Ç׿ø°æÀï
  • antigen excess
    Ç׿ø°úÀ×
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen recognition
    Ç׿øÀÎÁö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • HLA antigen
    HLAÇ׿ø.
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
  • I antigen
    I Ç׿ø
  • I region-associated antigen
    Ir¿¬°üÇ׿ø
  • Ia antigen
    IaÇ׿ø
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
  • K antigen
    K Ç׿ø.
  • K antigen
    K Ç׿ø.
  • K antigen
    K Ç׿ø.
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • Kidd antigen
    Kidd Ç׿ø
  • LD antigen
    LDÇ׿ø
  • LW antigen
    LW Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cross reactivation
    ±³Â÷ÀçȰ¼ºÈ­(¡­üÀàõûù).
  • cross reactivation
    ±³Â÷Ȱ¼ºÈ¸º¹.[»ýÈ­]±³Â÷Ȱ¼ºÈ­(¡­üÀàõûù).
  • cross reactivation
    ±³Â÷Ȱ¼ºÈ¸º¹.[»ýÈ­]±³Â÷Ȱ¼ºÈ­(¡­üÀàõûù).
  • cross reactivation
    ±³Â÷ÀçȰ¼ºÈ­
  • cross reactivity
    ±³Â÷¹ÝÀÀ¼º.
  • cross reactivity
    ±³Â÷ ¹ÝÀÀ
  • cross relaxation
    ±³Â÷ ÀÌ¿Ï
  • cross resistance
    ±³Â÷ÀúÇ×.
  • cross resistance
    ±³Â÷ÀúÇ×.
  • cross resistance
    ±³Â÷³»¼º
  • cross section radiography
    ´ÜÃþÃÔ¿µ¼ú
  • cross sectional echocardiogram
    ´ÜÃþ½ÉÃÊÀ½ÆÄµµ.
  • cross sectional echocardiography
    ´ÜÃþ½ÉÃÊÀ½ÆÄ°Ë»ç.¹æ»ç¼±´ÜÃþ½É¿¡ÄÚ °Ë»ç.
  • cross sectional echocardiography
    ´ÜÃþ½ÉÃÊÀ½ÆÄ°Ë»ç
  • cross sensitization
    ±³Â÷°¨°¢(Îßó©ÊïÊÆ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • soluble antigen
    °¡¿ëÇ׿ø(ʦéÁù÷ê«)
  • surface antigen
    Ç¥¸éÇ׿ø (øúØüù÷ê«)
  • t antigen
    t Ç׿ø(ù÷ê«)
  • T antigen
    T Ç׿ø(ù÷ê«)
  • Thy-1-antigen
    Thy-1-Ç׿ø(ù÷ê«)
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tolerogenic antigen
    ³»¼º»ý¼º Ç׿ø (Ò±àõßæà÷ù÷ê«)
  • transplantation antigen
    ÀÌ½Ä Ç׿ø(ì¹ãÕù÷ê«)
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • V antigen
    V Ç׿ø(ù÷ê«)
  • Vi antigen
    Vi Ç׿ø (ù÷ê«)
  • virus antigen
    ¹ÙÀÌ·¯½º Ç׿ø (ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
RH radiant heat; radiation hybrid; radiological health; reactive hyperemia; recurrent herpes; regulator...
RHBF reactive hyperemia blood flow
RND radical neck dissection; radionuclide dacryography; reactive neurotic depression
ROI reactive oxygen intermediate; region of interest; right occipitolateral [fetal position]
ROS reactive oxygen species; review of systems; rod outer segment
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
T-antigen Thomsen Friedenreich antigen
T-antigen Tumor antigen
TBARS 2-Thiobarbituric acid-reactive substances
TBARS 2-thiobarbituric reactive substances
CRP C - reactive protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • N-antigen
    N Ç׿ø
  • nuclear antigen
    ÇÙ Ç׿ø
  • pancreatic oncofetal antigen
    ÃéÀåÀÇ Å¾Ƽº ¾Ï Ç׿ø
  • pollen antigen
    ²É°¡·ç Ç׿ø, È­ºÐ Ç׿ø
  • polyvalent antigen
    ´Ù°¡ Ç׿ø
  • self antigen
    ÀÚ±â Ç׿ø
  • somatic antigen
    ±Õü Ç׿ø, ü¼¼Æ÷ Ç׿ø
  • treponema antigen test
    Æ®·¹Æ÷³×¸¶ Ç׿ø ½ÃÇè
  • tumor associated antigen
    ¾Ï °ü·Ã Ç׿ø
    ÀϺÎÀÇ Á¤»ó ¼¼Æ÷¿¡¼­¸¸ ¹ß°ßµÇ¾î ÀÖÀ¸³ª ¾Ï ¼¼Æ÷¿¡¼­µµ ¸¹Àº ¹üÀ§¿¡¼­ ¹ßÇöµÈ Ç׿ø, Á¤»ó ¼¼Æ÷¿¡¼­´Â ¹Ì·®ÀÌ Á¸ÀçÇϳª ¾Ï ¼¼Æ÷¿¡¼­´Â ´Ù·®ÀÌ °ËÃâµÇ´Â Ç׿ø, ±×·¯³ª °áÄÚ ¾Ï ƯÀÌÀûÀ̶ó°í ÇÒ ¼ö ¾ø´Â ¼ºÁúÀÇ Ç׿ø.
  • viral capsid antigen
    ¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø, ¹ÙÀÌ·¯½º¼º ĸ½Ãµå Ç׿ø
  • virus bound antigen
    ¹ÙÀÌ·¯½º °áÇÕ Ç׿ø
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
antigen shift Abrupt change in antigens expressed by a species or variety of organisms. Usually seen in microorganisms where the change may allow escape from immune recognition. Antigenic drift is a more gradual change.
See: antigenic variation.
(18 Nov 1997)
antigen unit The smallest amount of antigen that, in the presence of specific antiserum, will fix 1 complement unit.
(05 Mar 2000)
aspergillus antigen skin test <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis.
(27 Sep 1997)
Au antigen Auberger blood group
Aus antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
Australia antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
B-cell antigen receptors In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors.
(05 Mar 2000)
becker antigen bea antigen
blood group antigen <haematology, immunology> The set of cell surface antigens found chiefly, but not solely, on blood cells.
More than fifteen different blood group systems are recognised in humans. There may be naturally occurring antibodies without immunisation, especially in the case of the ABO system and matching blood groups is important for safe transfusion.
In most cases the antigenic determinant resides in the carbohydrate chains of membrane glycoproteins or glycolipids.
See: Rhesus, Duffy, Kell, Lewis and MN.
(25 Jun 1999)
cancer antigen 125 test Test for cell-surface antigen found on derivatives of coelomic epithelium. Elevated levels of this antigen are associated with ovarian malignancy and benign pelvic disease such as endometriosis.
(05 Mar 2000)
capsular antigen That found only in the capsules of certain microorganisms; e.g., the specific polysaccharides of various types of pneumococci.
(05 Mar 2000)
carcinoembryonic antigen <tumour marker> Antigen found in blood of patients suffering from cancer of colon and some other diseases, that is otherwise normally found in foetal gut tissue.
(19 Jan 1998)
macrophage-1 antigen An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
V antigen Viral antigen that is intimately associated with the virus particle, is protein in nature, has multiple antigenicities, and is strain-specific; antibody to such antigen is demonstrable as protective or neutralizing antibody.
(05 Mar 2000)
variable antigen <immunology> Term usually applied to the surface antigens of those parasitic or pathogenic organisms that can alter their antigenic character to evade host immune responses. (See antigenic variation).
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cross-legged
    ¹ßÀ» Æ÷°µ(Æ÷°³°í);Ã¥»ó´Ù¸®¸¦ ÇÑ(Çϰí)
  • cross-license
    (´Ù¸¥ ȸ»ç¿Í)»óÈ£ ƯÇã »ç¿ë °è¾àÀ» ¸Î´Ù
  • cross-link
    ±³Â÷ °áÇÕ(¿øÀÚ±º);±³Â÷ °áÇÕ½ÃŰ´Ù(ÇÏ´Ù)
  • cross-match
    (¼öÇ÷ Àü¿¡)±³Â÷(ÀûÇÕ)½ÃÇèÀ» ÇÏ´Ù
  • cross-modal
  • cross-ownership
    (½Å¹®»ç¿Í ¶óµð¿À.ÅÚ·¹ºñÀü ȸ»çÀÇ)°øµ¿¼ÒÀ¯
  • cross-polinate
    ÀÌÈ­¼öºÐ ½ÃŰ´Ù
  • cross-polination
    ÀÌÈ­ ¼öºÐ
  • cross-purpose
    ¹Ý´ë ¸ñÀû;(ÀÇÇâÀÇ) »óÄ¡;µ¿¹®¼­´ä½Ä ¹®´ä³îÀÌ
  • cross-question
    ¹Ý´ë½É¹®ÇÏ´Ù(crossexamine);¹Ý¹®;Èú¹®
  • cross-refer
    ÀüÈÄ(»óÈ£)ÂüÁ¶ÇÏ´Ù;(µ¶ÀÚ¿¡°Ô)»óÈ£ ÂüÁ¶½ÃŰ´Ù
  • cross-reference
    (°°Àº üÁßÀÇ)ÀüÈÄ(»óÈ£)ÂüÁ¶;=CROSS-REFER
  • cross-sectional
    Ⱦ´Ü¸éÀÇ;(Àüü¸¦ ´ëÇ¥ÇÏ´Â)´Ü¸éÀÇ
  • cross-sectional X-ray
    ´ÜÃþ¸é X¼±
  • cross-staff
    Á÷°¢±â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á